Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bipolar Disorder
Divalproex comparable to lithium in efficacy and cost
August 15th, 2005
For the treatment of bipolar disorder, divalproex is comparable to lithium in terms of efficacy and cost. In a recent study from Maryland, the "clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year." "In a pragmatic, randomized clinical trial, 201 adults hospitalized with bipolar I manic or mixed episodes were randomized to divalproex or lithium, in addition to usual psychiatric care, and followed for 1 year," explained D.A. Revicki and coauthors working at Bethesda-based MEDTAP International. "All subsequent treatment of bipolar disorder was...
Source: Pharma Business Week (2005-08-15)
|
